title: The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer.
abstract: Bacillus Calmette-Guérin (BCG) has been used for many years to treat cancer of the urinary bladder. It constitutes effective intravesical therapy of carcinoma in situ and recurrent superficial bladder cancer. Although the mechanism of action is unknown, most evidence suggests an immune-mediated mechanism. BCG treatment is known to increase cytokine production in the urinary bladder. As cytokines may induce nitric oxide synthase (NOS) activity and as nitric oxide (NO) exerts cytotoxic effects on tumour cells, we investigated the role of NO in BCG-mediated anti-tumour activity. Here we demonstrate a marked induction of both calcium-dependent and calcium-independent NOS activity in the human urinary bladder after BCG treatment. The presence of NOS in the urothelial cells was also demonstrated by the use of immunohistochemistry. Furthermore, patients treated with BCG showed a 30 times higher production of gaseous NO as measured in the urinary bladder by chemiluminescence. Finally, NO donors exerted cytotoxic effects on bladder cancer cell lines. These findings suggest that NO synthesis may be an important mechanism in BCG-mediated anti-tumour therapy.
authors.affiliation: Department of Surgery, Karolinska Hospital, Sweden.
authors.forename: O T
authors.initials: OT
authors.lastname: Jansson
authors.forename: E
authors.initials: E
authors.lastname: Morcos
authors.forename: L
authors.initials: L
authors.lastname: Brundin
authors.forename: J O
authors.initials: JO
authors.lastname: Lundberg
authors.forename: J
authors.initials: J
authors.lastname: Adolfsson
authors.forename: M
authors.initials: M
authors.lastname: Söderhäll
authors.forename: N P
authors.initials: NP
authors.lastname: Wiklund
mesh_terms: D001500:BCG Vaccine / Q000494:pharmacology / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D002291:Carcinoma, Papillary / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D002470:Cell Survival; D004273:DNA, Neoplasm / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D008163:Luminescent Measurements; D009569:Nitric Oxide / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D019459:Urothelium / Q000378:metabolism / Q000473:pathology
chemical_list: D001500:BCG Vaccine; D004273:DNA, Neoplasm; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase